ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Conditions

• ATTR Amyloidosis
• Transthyretin-Mediated Amyloidosis

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Study Details

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients * Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting * Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant

Key Dates

Start date

Nov 23, 2020

Status verified

May 2026

Primary completion

Dec 31, 2033

Completion

Dec 31, 2033

Study Design

Enrollment

1,500 participants (estimated)

Arms

• Arm: Patients with ATTR amyloidosis
  Patients with a diagnosis of ATTR amyloidosis, hereditary or wild type, will be eligible for the study and will follow routine clinical care.
• Arm: Pre-symptomatic Carriers
  Pre-symptomatic carriers with a known disease-causing TTR variant will be eligible for the study and will follow routine clinical care.

Primary Outcome Measure

Incidence of Adverse Events [ Time Frame: From time of enrollment for up to 10 years ]

Central Contacts

• Alnylam Clinical Trial Information Line
  1-877-ALNYLAM
  [email protected]
• Alnylam Clinical Trial Information Line
  1-877-256-9526
  [email protected]

Locations (13)

Find similar trials in La Jolla, CA

Related Studies

• OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
  Recruiting · AstraZeneca · Eden Prairie, Minnesota